Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
NCT05841758Phase 4Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2024
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in sarcoidosis comparing Hydroxychloroquine with Placebo arm (2 arms). Primary endpoint: Steroid-sparing effect of hydroxychloroquine at 1 year. Started Jul 2024; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on NCT05841758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841758.